Targeted COVID-19 treatment using neutralizing antibody

Pending a vaccine and other effective treatments, Norimun AS, together with NTNU and Oslo University Hospital (OUS), has taken the initiative to produce targeted antibodies against SARS-CoV-2, the virus that causes COVID-19. To meet the demand for antibodies that can neutralize SARS-CoV-2, it must be produced in large quantities at a cost-effective price. Furthermore, antibody formulations that meet medical safety requirements must be prepared and a clinical trial on humans must be designed. An effective antibody preparation, which acts as a passive immunization, will be of great benefit to critically ill patients but also to healthcare professionals who are exposed to a high risk of infection. The main objective of the project is to produce antibodies with a neutralizing effect that can be offered to COVID-19 patients and administered either orally, by inhalation or by transfusion.